TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
02617.HK stock price ended at $0 on 금요일, after dropping NaN%
On the latest trading day Jan 30, 2026, the stock price of 02617.HK fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for 02617.HK decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.
02617.HK 기술적 시그널
기술적 시그널 요약
구매 신호 0
중립 신호 7
매도 신호 0
Strong Sell
Sell
Neutral
Buy
Strong Buy
02617.HK은 현재 0개의 매수 신호와 0개의 매도 신호를 보이고 있습니다. 이 주식은 -- 이후로 하락 추세 상태에 있으며, 이 기간 동안 총 가격 변동률은 --입니다. 전반적으로 기술적 지표들은 중기적으로 Neutral 전망을 나타내고 있습니다.
02617.HK에 대한 강세/약세 신호
이동평균, RSI, MACD, 거래량 등 핵심 지표를 분석하여 02617.HK 의 강세/약세 시그널을 생성합니다. 이 인사이트를 활용해 더 현명한 투자 결정을 내리세요.
다음 질문
기술 분석 지표는 02617.HK에 어떻게 적용됩니까?
TransThera Sciences (Nanjing), Inc.의 RSI는 얼마입니까?
다음 12개월 동안 TransThera Sciences (Nanjing), Inc.의 가격은 얼마입니까?
TransThera Sciences (Nanjing), Inc.는 얼마나 높이 갈 것으로 예상됩니까?